Log In Get Started
Stock Markets March 18, 2026

FDA Clears J&J's First Oral Psoriasis Treatment, Opening New Competitive Front in Immunology

Icotyde approved for adults and adolescents with moderate-to-severe plaque psoriasis; J&J aims to capture share with once-daily oral therapy

By Avery Klein
FDA Clears J&J's First Oral Psoriasis Treatment, Opening New Competitive Front in Immunology

The U.S. Food and Drug Administration has approved Johnson & Johnson's oral psoriasis pill, Icotyde, for adults and pediatric patients 12 years and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis. The approval positions J&J to expand into the psoriasis market with a once-daily oral alternative that has shown superior skin clearance versus an established oral competitor in head-to-head trials. The company has not yet provided pricing or availability details.

Key Points

  • FDA has approved Johnson & Johnson's oral psoriasis pill, Icotyde, for adults and pediatric patients 12 years and older weighing at least 40 kg with moderate-to-severe plaque psoriasis.
  • Icotyde, developed with Protagonist Therapeutics and chemically known as icotrokinra, blocks IL-23 and has shown superior skin clearance versus Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
  • The approval introduces a once-daily oral competitor to existing therapies such as Sotyktu and AbbVie's Skyrizi and arrives as J&J's injectable Stelara faces increased competition from low-cost copycats.

The U.S. Food and Drug Administration has granted approval to Johnson & Johnson's oral medication for psoriasis, the company announced on Wednesday. Branded as Icotyde, the pill is cleared for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients aged 12 years and older who weigh at least 40 kg.

The approval provides a non-injectable treatment option for patients with the chronic autoimmune condition that produces itchy, scaly, and inflamed skin patches. J&J has positioned Icotyde as a once-daily oral therapy that could simplify treatment for patients seeking ease of use, skin clearance, and a favorable safety profile.

Icotyde, chemically known as icotrokinra, was developed in partnership with Protagonist Therapeutics. The medication works by blocking IL-23, a protein involved in inflammatory responses - the same biological target as some existing therapies. Like AbbVie's Skyrizi and J&J's own Tremfya, Icotyde targets IL-23 pathways to reduce inflammation.

In two late-stage head-to-head trials, Icotyde demonstrated superior skin clearance compared with Bristol Myers Squibb's oral treatment Sotyktu. Wall Street analysts have described Icotyde as having "blockbuster potential" given its safety profile and oral, once-daily dosing, with expectations that it could capture meaningful market share.

David Lee, J&J's global head of immunology, said patients have been seeking complete skin clearance, a favorable safety profile, and the simplicity of a once-daily pill. "We see Icotyde as becoming the first-line systemic therapy for psoriasis patients," he said.

The new oral option will compete directly with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi. The approval also comes as J&J's established injectable Stelara is facing mounting competition from lower-cost copycat drugs, a dynamic that has encouraged the company to broaden its portfolio.

J&J is continuing studies of icotrokinra in additional inflammatory conditions. The company is evaluating the drug for ulcerative colitis, psoriatic arthritis, and Crohn's disease, though those indications remain under investigation and have not been approved.

J&J has not yet provided details on pricing or the timeline for availability following the regulatory decision. The absence of immediate information on cost and market rollout leaves questions about uptake and commercial dynamics unanswered for now.

Sectors impacted: Pharmaceuticals, biotechnology, healthcare services and specialty therapeutics.

Risks

  • Pricing and availability have not been announced, creating uncertainty about commercial uptake and access - this affects pharmaceutical revenue forecasts and payer budgets.
  • Icotyde will face direct competition from established therapies including Sotyktu and Skyrizi, introducing market-share risk in the psoriasis treatment segment - this impacts specialty pharmaceutical market dynamics.
  • Additional clinical development is ongoing for other indications such as ulcerative colitis, psoriatic arthritis, and Crohn's disease, meaning future expansion is uncertain and contingent on study outcomes - this impacts pipeline valuation and long-term growth assumptions.

More from Stock Markets

Researchers Find Widespread iPhone Spyware Planted on Ukrainian Websites Mar 18, 2026 Anthropic Gains Dominant Share of New Enterprise AI Spending, Mizuho Flags Winners Mar 18, 2026 Rothschild Moves Block to Neutral as Valuation Reframes; Cautions on Rising Loan Losses Mar 18, 2026 GM Says Recent Fuel Price Rise Has Not Altered Sales Trend Mar 18, 2026 Gulf States Move to Cripple Iran’s Ruling Regime as Strait of Hormuz Is Shut Mar 18, 2026